BioCentury | Jun 1, 2019
Product Development

ASCO 2019 abstracts show solid tumor race heating up among bispecifics and CAR Ts

While strong progress in CAR T therapies will again feature at this year’s ASCO meeting, bispecific antibodies are having a moment -- making more inroads into solid tumors than CAR Ts and branching out via...
BC Innovations | Jan 3, 2019
Translation in Brief

New Therapeutic Targets and Biomarkers: December 2018

New Therapeutic Targets and Biomarkers: December 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December. Therapeutic targets are defined as any protein, gene or other molecule...
BC Innovations | Dec 19, 2018
Distillery Therapeutics

Hematology

INDICATION: Bleeding In vitro and human plasma studies identified a peptide-based plasmin inhibitor that could help treat bleeding. Chemical synthesis and in vitro testing of analogs of a sunflower cyclic peptide serine protease inhibitor in...
BC Innovations | Dec 11, 2018
Distillery Techniques

Disease models

TECHNOLOGY: Animal models Mice with activated PRSS1 could be used to screen therapies to treat acute and chronic pancreatitis. Mice engineered to express a mutant, activated mouse homolog of PRSS1 recapitulated the pancreatic edema, neutrophil...
BC Innovations | Sep 26, 2018
Distillery Therapeutics

Cancer

INDICATION: Sarcoma; pancreatic cancer In vitro and mouse studies identified an amiloride-based PLAU inhibitor that could help treat metastatic fibrosarcoma and pancreatic cancers. Chemical synthesis and in vitro testing of amiloride analogs in enzyme activity...
BC Week In Review | May 25, 2018
Company News

Takeda divests stake in Chinese JV Techpool

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) spokesperson Vince Docherty told BioCentury on May 23 that the pharma's divestment of critical care and API manufacturing JV Guangdong Techpool Bio-Pharma Co. Ltd. (Guangzhou, China) does not signal a...
BC Extra | May 23, 2018
Company News

Takeda divests stake in Chinese JV

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) spokesperson Vince Docherty told BioCentury on Wednesday that the pharma's divestment of critical care and API manufacturing JV Guangdong Techpool Bio-Pharma Co. Ltd. (Guangzhou, China) does not signal a strategic...
BC Week In Review | Nov 30, 2017
Company News

Catalyst, Mosaic partner to develop anti-C3 proteases for dry AMD

Catalyst Biosciences Inc. (NASDAQ:CBIO) partnered with Mosaic Biosciences Inc. (Boulder, Colo.) to develop Catalyst’s preclinical anti-complement 3 (C3) proteases, including CB 2782, to treat dry age-related macular degeneration (AMD) and other inflammatory and retinal disorders....
BC Innovations | Dec 8, 2016
Product R&D

Unmarked territory

While the predictive power and standardization of PD-L1 diagnostics is still being hashed out by clinical immuno-oncologists, companies and academics are casting a wide net for better biomarkers to forecast patient responses to checkpoint inhibitors....
BC Week In Review | Sep 19, 2016
Clinical News

LB1148: Phase II started

Leading BioSciences began the double-blind, placebo-controlled, international Phase II PROFILE trial to evaluate 700 mL oral LB1148 given 8-10 hours before undergoing elective bowel resection in about 120 patients. Leading BioSciences Inc. , San Diego, Calif....
Items per page:
1 - 10 of 167